Navigation Links
Agendia and Ferrer Announce Exclusive Agreement for Sales of Cancer Diagnostic Services in Four Major European Markets
Date:7/15/2008

AMSTERDAM, The Netherlands and BARCELONA, Spain, July 15 /PRNewswire-FirstCall/ -- Agendia BV and Ferrer inCode today announced an agreement that will give Ferrer exclusive rights to sell two of Agendia's signature cancer diagnostic services -- MammaPrint(R), a prognostic test that uses a 70-gene signature to indicate risk of breast cancer tumor recurrence, and CupPrint*, a gene expression profiling service which offers a fast and reliable method of identifying the primary tumor site in Cancer of Unknown Primary (CUP). Under the exclusive distribution agreement, Ferrer has gained rights to sell the tests in Germany, France, Italy, and Portugal, in addition to a current agreement signed in 2007 covering Spain.

"We are confident that Ferrer inCode is the right partner for the successful expansion of MammaPrint and CupPrint into these additional European markets," said Dr. Bernhard Sixt, president and chief executive officer of Agendia. "This agreement will allow us to increase the availability of our services to more customers in these countries, with the result being that more patients and their physicians will have access to the valuable information provided by these tests."

MammaPrint is a clinically proven, highly accurate gene expression profiling test that offers healthcare professionals a unique personalized prognostic analysis to determine a patient's individual risk of recurrence of breast cancer. MammaPrint, the first In Vitro Diagnostic Multivariate Index Assay (IVDMIA) to acquire market clearance from the U.S. Food and Drug Administration (February 2007) provides information that helps physicians and patients to make more effective treatment decisions, which may include minimizing the use of chemotherapy, thereby avoiding serious potential side-effects. CupPrint* is an innovative diagnostic service that identifies the origin of the primary tumor in Cancer of Unknown Primary, which accounts for up to five percent of all new cancer refer
'/>"/>

SOURCE Agendia BV
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Agendia BV Appoints Mr. Hessel Lindenbergh as Chairman of its Supervisory Board
2. Agendia Joins the Personalized Medicine Coalition (PMC)
3. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
4. Agendia BV Announces That its Chief Research Officer Laura van t Veer has Received a 2007 Breast Cancer Research Foundation Award
5. Agendia BV Appoints Clinical and Scientific Advisory Board
6. Agendia and Agilent Announce Plans to Jointly Develop New Diagnostic Tests, Extend Supply Agreement
7. Agendias MammaPrint(R) Receives Prestigious Award From Dutch Innovation Platform
8. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
11. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)..., , NEW YORK, Dec. 1 R...ch report is available in its catalogue: ,, In...http://www.reportlinker.com/p0164431/Industrial-En...ial Enzymes market is an oligopoly with few strong...niche market activities. Keen competition and comm...
(Date:12/1/2009)..., , Former Majority Leader Richard Geph...nce, Medicine, Biotech Communities for "Best and ...SEY CITY, N.J., Dec. 1 ...biopharmaceuticals, research, medicine and technol...o discuss the importance of medical innovation in ...
(Date:12/1/2009)..., , SAN FRANCISCO, Dec. 1 Th...k almost half the value it lost in October. The Se...an excellent month for the general markets with th... in value. The gains held firm in the final two tr...bout sluggish Thanksgiving holiday shopping and Du...
(Date:12/1/2009)..., , CRANBURY, N.J., Dec. 1 /PRNewswire-First...TN ) today announced that the U.S. Patent and Trad... titled "Cyclic Natriuretic Peptide Constructs." ...cyclic compounds that bind to natriuretic peptide ...ad heart failure drug candidate. ,, "Our natriu...
Breaking Biology Technology:Reportlinker Adds Industrial Enzymes - A Global Market Report 2Reportlinker Adds Industrial Enzymes - A Global Market Report 3Reportlinker Adds Industrial Enzymes - A Global Market Report 4Reportlinker Adds Industrial Enzymes - A Global Market Report 5Reportlinker Adds Industrial Enzymes - A Global Market Report 6Reportlinker Adds Industrial Enzymes - A Global Market Report 7Reportlinker Adds Industrial Enzymes - A Global Market Report 8Reportlinker Adds Industrial Enzymes - A Global Market Report 9Reportlinker Adds Industrial Enzymes - A Global Market Report 10New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 2New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 3New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 4New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 5Biotech Gets Back on Track in November 2Biotech Gets Back on Track in November 3Biotech Gets Back on Track in November 4Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate 2Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate 3
... VALLEY COTTAGE, N.Y., Feb. 5 XTL,Biopharmaceutic...ed notification,that on February 3, 2009 the Compa...ore than 5% of the Company,s outstanding ordinary ...y shareholders, meeting (EGM) of the Company as,so...g matters: , 1. that Boaz Shweiger be and is h...
... TOKYO, February 5 HOYA Corporation today,announc...ecember 31, 2008.,Net sales were 112.7 billion yen... from 147.0 billion yen in the third quarter of 20...he product price resulting from global,economic do...ctro-Optics and,Vision Care, as well as PENTAX tha...
... CHAPEL HILL, N.C., Feb. 5 In today,s tough econo...y, even while focusing on,strategy and tactics to ...etter understand the resources dedicated by biopha...ons, a recent benchmark study was conducted by Bes...ewly published report,"Benchmarks for Optimizing M...
Other Biology Technology:XTL Biopharmaceuticals to Convene Extraordinary Shareholders' Meetings after Receipt of Shareholder Letter 2Hoya Announces Third Quarter and the First Nine Months Financial Results for FY2008 2New Study Provides Benchmarks for Optimizing Marketing Staff Levels to Drive Growth 2
(Date:12/2/2009)..., PHILADELPHIA Less acculturated Latino men ha...se who are more acculturated to U.S. culture, but ...tting smoking. Details of these findings are publi...ion , a journal of the American Association for Ca...cus on tobacco. , "Acculturation affects smoking...
(Date:12/2/2009)..., , PHILADELPHIA People who smoke their first ci...igher levels of cotinine, a by-product of nicotine...o smoke, regardless of the number of cigarettes sm...ect the risk of lung cancer, our results suggest t... be especially at risk for lung cancer," said rese...
(Date:12/2/2009)... PHILADELPHIA Assurance of a cancer-free status d...computerized tomography (CT) lung-cancer screening...chers wrote in a study published in Cancer Epidem... American Association for Cancer Research. The Dec..., These findings should negate widespread concern...
Breaking Biology News(10 mins):Acculturation affects smoking cessation success among Latinos 2Increased nicotine levels detected in those who light-up earlier 2Repeat negative CT scan for lung cancer does not encourage ex-smokers to resume the habit 2Second hand smoking results in liver disease study finds 9877 1Second hand smoking results in liver disease study finds 9877 2Ritter Pharmaceuticals Hires Dr Howard Foyt as Executive Vice President Development 26 Chief Medical Officer 56849 1Ritter Pharmaceuticals Hires Dr Howard Foyt as Executive Vice President Development 26 Chief Medical Officer 56849 2ADA FDI World Dental Federation Observe World Oral Health Day 56846 1ADA FDI World Dental Federation Observe World Oral Health Day 56846 2
...07 In a paper published today in the journal Scie... and academic colleagues from the National Univers...n Sweden report the discovery of two common single...uman genome that appear to account for virtually a...are located in the LOXL1 gene on chromosome 15, an...
...cer therapy by blocking the molecular motors invol...ision is being pursued by young Dutch researcher D...inning projects sponsored by the European Science ...h Councils (EuroHORCS). Dekker and her team are t...h the molecular motors that copy DNA during cell d...
..., researchers report for the first time that genet...ures harboring DNA that are inherited only from th...or type 2 diabetes. The study, which highlights t...athogenesis of common diseases, is published onlin...rding to the Centers for Disease Control, 7% of th...
Other Biology News:deCODE discovers cause of major subtype of glaucoma 2ESF EURYI award winner aims to stop cancer cells reading their own DNA 2Scientists show that mitochondrial DNA variants are linked to risk factors for type 2 diabetes 2
...internal standard for the quantification of 5-OxoE...-OxoETE is a polyunsaturated keto acid formed by t...imulates cytosolic calcium levels in neutrophils w...es the migration and degranulation of eosinophils ...
...0 kb Autographa californica (AcNPV) polyhedrin loc...NPV polyhedrin promoter and two AcNPV p10 promoter... cloning site, followed by polyhedrin locus-derive...rted polyhedrin promoter has been inserted contain...
...Delivers 4,600 to Over 3 Million Genotypes Per Day...ble of performing 4,600 to over 3 Million genotype...s*, this automated, scalable, multiplexed system c...d 384-well plate, for cost-effective high throughp...
Mouse Anti-HD Monoclonal Antibody, Unconjugated, Clone 3D6 from Abnova Corporation
Biology Products: